The introduction of Retatrutide ZPHC, at a dosage of 120mg, is generating considerable buzz within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to provide impressive improvements in weight reduction compared to existing therapies. Initial patient studies have i